Management of High-Risk Upper GI Bleeding
For adult patients with high-risk upper GI bleeding, perform endoscopy within 24 hours after initial resuscitation, apply endoscopic hemostatic therapy to high-risk stigmata (active bleeding or visible vessel), and administer high-dose intravenous PPI therapy (bolus followed by continuous infusion) for 3 days post-endoscopy. 1
Initial Resuscitation and Stabilization
Begin with aggressive fluid resuscitation using normal saline or lactated Ringer solution to correct hypovolemia and maintain blood pressure 2. Transfuse red blood cells at a hemoglobin threshold of 7 g/dL (or 8 g/dL if cardiovascular disease or active myocardial ischemia is present) 1, 3. This restrictive transfusion strategy improves outcomes compared to liberal transfusion.
Obtain immediate laboratory testing: complete blood count, basic metabolic panel, coagulation studies, liver function tests, and type and crossmatch 2. Assess hemodynamic stability continuously—heart rate, blood pressure, and signs of ongoing bleeding guide resuscitation intensity.
Pre-Endoscopic Pharmacologic Management
Administer intravenous proton pump inhibitors immediately upon presentation 2. While pre-endoscopic PPIs may reduce endoscopic stigmata of bleeding, they do not improve mortality or rebleeding rates 4. However, they are low-risk and widely recommended.
Give intravenous erythromycin (250 mg) 30-60 minutes before endoscopy to improve gastric emptying and visualization 3, 5. This prokinetic agent significantly increases diagnostic yield at first endoscopy by clearing blood and clots from the stomach.
If variceal bleeding is suspected (cirrhosis, portal hypertension), immediately start antibiotics and vasoactive drugs (octreotide or terlipressin) before endoscopy 5, 6. Variceal hemorrhage carries higher mortality than non-variceal bleeding and requires urgent specific therapy.
Timing of Endoscopy
Perform endoscopy within 24 hours of presentation for all hospitalized patients with upper GI bleeding 1, 3. This is the standard recommendation across all major guidelines. The evidence does not support routine ultra-early endoscopy (within 6-12 hours) for most high-risk patients, as outcomes are similar to endoscopy within 24 hours after adequate resuscitation 1.
Critical caveat: Patients with hemodynamic instability despite resuscitation or ongoing massive bleeding may benefit from earlier endoscopy, but only after initial stabilization attempts 2. Never rush to endoscopy before addressing life-threatening hypovolemia.
For suspected variceal bleeding specifically, consider endoscopy within 12 hours, as this population may benefit from earlier intervention 6.
Endoscopic Hemostatic Therapy
Apply endoscopic therapy to all ulcers with active spurting or oozing bleeding and to non-bleeding visible vessels 3, 4. These high-risk stigmata (Forrest Ia, Ib, and IIa) have rebleeding rates of 40-90% without treatment.
Recommended endoscopic modalities include 1, 3:
- Bipolar electrocoagulation or heater probe (thermal methods)
- Through-the-scope clips (mechanical method)
- Sclerosant injection (epinephrine plus a second modality)
Combination therapy is superior to monotherapy—use epinephrine injection plus a thermal or mechanical method 4. Never use epinephrine injection alone, as it has higher rebleeding rates.
For adherent clots (Forrest IIb), endoscopic therapy may be considered, though evidence is mixed 4. Flat pigmented spots (Forrest IIc) and clean-based ulcers (Forrest III) do not require endoscopic therapy 4.
Hemostatic powder (TC-325) can be used as temporizing therapy for actively bleeding ulcers but should not be sole treatment—definitive hemostatic therapy must follow 1.
Post-Endoscopic Pharmacologic Management
After successful endoscopic hemostasis of high-risk lesions, administer high-dose intravenous PPI: 80 mg bolus followed by 8 mg/hour continuous infusion for 72 hours 1, 3. This regimen significantly reduces rebleeding and mortality compared to standard-dose or intermittent PPI therapy.
Following the 3-day infusion, transition to oral PPI twice daily for 14 days, then once daily 1. Total duration depends on the underlying cause—continue until H. pylori eradication is confirmed, NSAIDs are discontinued, or the ulcer etiology is addressed 4.
Management of Rebleeding
If bleeding recurs after initial successful hemostasis, perform repeat endoscopy with second attempt at endoscopic therapy 3, 5. Success rates for second endoscopic treatment are reasonable (approximately 70-80%).
If endoscopic therapy fails twice or bleeding is uncontrolled, proceed to transcatheter arterial embolization (TAE) rather than immediate surgery 3, 5. TAE has become the preferred second-line intervention, with lower morbidity than emergency surgery. Surgery is reserved for cases where TAE fails or is not feasible.
Special Considerations for Non-Peptic Ulcer Bleeding
For high-risk bleeding from malignant tumors, consider topical hemostatic agents over conventional endoscopic therapy, and arrange oncologic therapy after endoscopic intervention 7.
For Dieulafoy's lesions with active bleeding, use mechanical modalities (clips or band ligation) or contact thermocoagulation rather than epinephrine alone 7. These lesions are arterial and require robust hemostasis.
Common Pitfalls to Avoid
- Do not delay resuscitation to perform endoscopy—stabilize first, scope second
- Do not use epinephrine injection as monotherapy—always combine with thermal or mechanical method
- Do not continue anticoagulation during active bleeding—reverse if necessary, but plan early resumption (typically within 7 days) for cardiovascular indications 5, 4
- Do not use nasogastric tube lavage for diagnosis—it does not change management and may delay definitive care 6
- Do not intubate routinely for airway protection—reserve for patients with massive hematemesis, altered mental status, or respiratory failure, as intubation carries risks in this population 6